Recent therapeutic success with the anti-interleukin-4 (IL-4) receptor α antibody dupilumab suggests the pivotal role of IL-4 and IL-13 in the pathogenesis of AD because dupilumab interferes with both IL-4 and IL-13 signaling [14]. The gene discussed is IL4; the disease is Alzheimer disease.